AI-328

AI-328 is a bispecific antibody developed by Apeximmune Therapeutics as part of its Macrophage Engaging Bispecific Antibody (MEBA) platform. It is designed to treat both solid and hematologic cancers by simultaneously targeting AIM-104 and a tumor-associated antigen (TAA1). The drug's mechanism of action involves inhibiting AIM-104 to release the 'don't eat me' signal and activate macrophage phagocytic activity, while binding to TAA1 to direct the macrophages specifically toward tumor cells. This dual-targeting approach is intended to enhance anti-tumor immunity by leveraging the innate immune system to achieve tumor-specific killing.